Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study

Renee Heffron, Deborah Donnell, Prof Helen Rees, Connie Celum, Nelly Mugo, Edwin Were, Guy de Bruyn, Edith Nakku-Joloba, Kenneth Ngure, James Kiarie, Robert W Coombs, Jared M Baeten

Lancet Infect Dis. 2012 Jan;12(1):19-26. Epub 2011 Oct 3.

Hormonal contraceptives are used widely but their effects on HIV-1 risk are unclear. Heffron and colleagues aimed to assess the association between hormonal contraceptive use and risk of HIV-1 acquisition by women and HIV-1 transmission from HIV-1-infected women to their male partners. In this prospective study, they followed up 3790 heterosexual HIV-1-serodiscordant couples participating in two longitudinal studies of HIV-1 incidence in seven African countries. Among injectable and oral hormonal contraceptive users and non-users, they compared rates of HIV-1 acquisition by women and HIV-1 transmission from women to men. The primary outcome measure was HIV-1 seroconversion. Cox proportional hazards regression and marginal structural modelling were used to assess the effect of contraceptive use on HIV-1 risk. Among 1314 couples in which the HIV-1-seronegative partner was female (median follow-up 18·0 [IQR 12·6–24·2] months), rates of HIV-1 acquisition were 6·61 per 100 person-years in women who used hormonal contraception and 3·78 per 100 person-years in those who did not (adjusted hazard ratio 1·98, 95% CI 1·06–3·68, p=0·03). Among 2476 couples in which the HIV-1-seronegative partner was male (median follow-up 18·7 [IQR 12·8–24·2] months), rates of HIV-1 transmission from women to men were 2·61 per 100 person-years in couples in which women used hormonal contraception and 1·51 per 100 person-years in couples in which women did not use hormonal contraception (adjusted hazard ratio 1·97, 95% CI 1·12–3·45, p=0·02). Marginal structural model analyses generated much the same results to the Cox proportional hazards regression. Women should be counselled about potentially increased risk of HIV-1 acquisition and transmission with hormonal contraception, especially injectable methods, andabout the importance of dual protection with condoms to decrease HIV-1 risk. Non-hormonal or low-dose hormonal contraceptive methods should be considered for women with or at-risk for HIV-1.

For abstract access click herehttp://www.ncbi.nlm.nih.gov/pubmed/21975269

Use of injectible hormonal contraceptives and risk of HIV-1 transmission

There have been suggestions about the increased HIV infection risk with the use of  hormonal contraception. Prior to this study, observational studies have suggested a possible link with observed increased risk of HIV infection with the use of hormonal contraceptives. This study of HIV serodiscordant couples , while not specifically designed to examine this issue, further provides evidence to the possible link between the use of ijectable contraceptive and increased HIV risk. The study showed a doubling of the risk of HIV acquisition for HIV-negative women using injectable DMPA (depot-medroxyprogesterone acetate) and a doubling of the risk of HIV transmission from HIV-positive women using DMPA to their seronegative partners.

Cate Hankins, the Scientific Adviser for UNAIDS notes that ‘while contraception improves the health of women and children worldwide, and plays a crucial role in helping women with, or at risk of, HIV infection to prevent the adverse social and health consequences of unintended pregnancies, it is important to examine the meaning and implication of these evolving evidences. In view of this, WHO and partners are convening a technical consultation in early 2012 to re-examine the totality of evidence on the potential effects of hormonal contraception and of intrauterine devices on HIV acquisition, disease progression, and infectivity/transmission to sexual partners. The need to conduct randomized controlled trials to determine whether hormonal contraception increases the risk of HIV acquisition in women and/or of HIV transmission to men will be assessed.  In the meantime, we need to reinforce the importance of correct and consistent condom use, regardless of whether another method of contraception is being used. It is and has been for decades the ‘dual protection’ message’.

While we wait for the outcome of the WHO consultative meeting, it is important for those in the field to be aware of the evolving evidence and its potential implications in the design of HIV prevention services for serodiscordant couples at the least. Below is the abstract of the study. 

Implication for HIV prevention research protocol development and review: It may be important that when researchers plan HIV prevention studies, it will be important to factor the role that injectible hormonal contraceptives can plan in HIV acquisition during the data analysis process.

End of project report: Building capacity of laypersons to communicate NPT trial results

The importance of building the capacity of  the community, including the media, in  understanding and communicating  biomedical HIV trial
results is well recognised. Not only will it ensure  effective media communication, it will also promote community engagement in media
discourse.
The project “Building Community Engagement in Vaccines Efforts in Canada and Africaâ€, is a North-South Collaboration involving NHVMAS, Southern African AIDS Trust, South Africa, and ICAD, Canada. The aim of the 3 years project was to assist community representatives and the media to understand and communicate HIV trial results.
The objectives of the project include among others to develop a toolkit and training package on New Prevention Technologies research and to deliver  training workshops to the community representatives and media/journalists in Canada, Nigeria and Southern Africa. NHVMAS administered the Nigerian regional component of this collaboration from January 2010 to September, 2011.
For this project, NHVMAS worked in partnership with CSOs, most at risk populations (MARPs) the print and electronic media in four
geopolitical zones in Nigeria namely LagosAbujaEnugu and Kaduna.  A focused training for media/journalists was conducted in Sagamu. At the end of the project, 64 members of CSO, 23 journalists, 18 health workers, one researcher, one policy maker and four students were trained over the 18 months
period of the project. Information, Education and communication materials comprising of 3 sets of posters on NPT were developed and produced.
Based on pretest, post test and post training evaluations, it was very clear the the project was able to increase the knowledge  and understanding of trainees on NPTs. There was increased media reporting/publications on NPT (reports aired on Lagos State radio and television, and published on print media-Vanguard, Tribune, Daily independent and the Nation). All the trainees met during the evaluation exercise had also integrated knowledge and skills gained during the training into their organisations’ community education and outreach activities. Other outcomes include the use of the training tool to design research literacy training for 16 peer leaders who work with FSWs, IDUs, MSMs and PLHIV.
As a next step, NHVMAS shall look for mechanisms to replicate the trainings in many more communities of CSOs, and for journalists. As a first step in this direction, the team (SAT, ICAD and NHVMAS) shall organise and abrigded version of the training at ICASA on the 4th of December 2011 between 1.00pm and 4.00pm at Harmony Hotel, Ethiopia. More details about the training will be sent out. For all those planning to be at ICASA, please put this on your calender and share the information with others.

A simpler tool for estimation of HIV incidence from cross-sectional, age-specific prevalence data

A simpler tool for estimation of HIV incidence from cross-sectional,
age-specific prevalence data

REFERENCES: Journal of Epidemiology and Community Health. 16 June 2010
AUTHORS: Rajan SS and Sokal
Dhttp://jech.bmj.com/content/early/2010/06/16/jech.2009.091959.short?q=w_jech_ahead_tab
Background HIV incidence estimates are crucial in understanding and predicting the HIV/AIDS epidemic and identifying sub-populations and regions most at risk for the epidemic. However, incidence estimation is a challenge due to the nature of the disease and type of data available. This paper aims to present a simple and creative HIV incidence estimation method for resource constrained settings with scarce data.

Methods The authors developed a simple user-friendly non-iterative spreadsheet estimation method, which can produce incidence estimates by age group using observed cross-sectional, age-specific HIV prevalence. Data from two prospective FHI microbicide Phase III clinical trials in Nigeria were used to validate the spreadsheet method. Since both the clinical trials involved condom use promotion to reduce HIV risk, the authors also used the AVERT software to estimate the extent of incidence reduction due to the intervention.
Results The spreadsheet incidence estimates after accounting for AVERT adjusted reductions, for age groups 18-20, 21-25 and 26-30 were: 1.69%, 0.96% and 1.12% in the SAVVY trial, and 2.11%, 1.47% and 1.28% in the CS trial respectively. The corresponding actual observed incidence rates were 1.62%, 2.39%, and 1.13% in the SAVVY trial and 1.93%, 1.78% and 1.40% in the CS trial.

Conclusion Comparisons of the spreadsheet-estimated incidence with the actual incidence from the clinical trials demonstrated that the method is reasonably accurate in its estimation. Because of the method’s limitations it should not be used to evaluate HIV/AIDS prevention interventions or without understanding the direction of the bias in
the case of an evolving HIV epidemic.

Age related HIV incidence among sex workers

Age related HIV incidence among sex workers

The result of the study below shows that the HIV incidence (rate of new HIV infection) among sex workers (the community with the highest HIV prevalence in Nigeria) is still low compared to countries like South Africa (with a HIV incidence as high as 5.0%). However, when you read the data shown in the abstract below, it is clear that the HIV incidence is highest in the age group 18 to 20 years in both the SAVVY and the CS3 trial. Is this a possible pointer to our target group among FSW in Nigeria?

Full paper can be accessed at
http://jech.bmj.com/content/early/2010/06/16/jech.2009.091959.short?q=w_jech_ahead_tab